Evaluation and Management of Pulmonary Arterial Hypertension in Congenital Heart Disease
By: Hassaan B Arshad and Valeria E Duarte
References
- Moons P, Bovijn L, Budts W, et al. Temporal trends in survival to adulthood among patients born with congenital heart disease from 1970 to 1992 in Belgium. Circulation. 2010 Nov 30; 122(22): 2264–72. doi: 10.1161/circulationaha.110.946343.
- Marelli AJ, Mackie AS, Ionescu-Ittu R, et al. Congenital Heart Disease in the General Population. Circulation. 2007 Jan 8; 115(2): 163–72. doi: 10.1161/circulationaha.106.627224.
- Engelfriet PM, Duffels MG, Möller T, et al. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. Heart. 2007 Jun; 93(6): 682–7. doi: 10.1136/hrt.2006.098848.
- Calabro P, Limongelli G, Maddaloni V, et al. Analysis of endothelin-1 and endothelin-1 receptor A gene polymorphisms in patients with pulmonary arterial hypertension. Intern Emerg Med. 2012 Oct; 7(5): 425–30. doi: 10.1007/s11739-011-0643-2.
- Duffels MGJ, Engelfriet PM, Berger RM, et al. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry. Int J Cardiol. 2007 Aug 21; 120(2): 198–204. doi: 10.1016/j.ijcard.2006.09.017.
- Diller GP, Dimopoulos K, Kaya MG, et al. Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease. Heart. 2007 Aug; 93(8): 974–6. doi: 10.1136/hrt.2006.089185.
- Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013 Dec 24; 62(25 Suppl): D34–41. doi: 10.1016/j.jacc.2013.10.029.
- Condon DF, Nickel NP, Anderson R, et al. The 6th World Symposium on Pulmonary Hypertension: what’s old is new. F1000Research. 2019 Jun 19; 8: F1000 Faculty Rev-888. doi: 10.12688/f1000research.18811.1.
- Baumgartner H, De Backer J. The ESC Clinical Practice Guidelines for the Management of Adult Congenital Heart Disease 2020. Eur Heart J. 2020 Nov 14; 41(43): 4153–4154. doi: 10.1093/eurheartj/ehaa701.
- Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 Apr 9; 139(14): e698–e800. doi: 10.1161/cir.0000000000000603.
- Arvanitaki A, Giannakoulas G, Baumgartner H, Lammers AE. Eisenmenger syndrome: diagnosis, prognosis and clinical management. Heart. 2020 Nov; 106(21): 1638–1645. doi: 10.1136/heartjnl-2020-316665.
- Beghetti M, Galiè N. Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Mar 3; 53(9): 733–40. doi: 10.1016/j.jacc.2008.11.025.
- Daliento L, Somerville J, Presbitero P, et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J. 1998 Dec 1; 19(12): 1845–55. doi: 10.1053/euhj.1998.1046.
- Kulik TJ. Pulmonary blood flow and pulmonary hypertension: Is the pulmonary circulation flowophobic or flowophilic? Pulm Circ. 2012 Jul; 2(3): 327–39. doi: 10.4103/2045-8932.101644.
- Lowe BS, Therrien J, Ionescu-Ittu R, et al. Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes. J Am Coll Cardiol. 2011 Jul 26; 58(5): 538–46. doi: 10.1016/j.jacc.2011.03.033.
- Brida M, Gatzoulis MA. Pulmonary arterial hypertension in adult congenital heart disease. Heart. 2018 Oct; 104(19): 1568–74. doi: 10.1136/heartjnl-2017-312106.
- Ridderbos FJ, Wolff D, Timmer A, et al. Adverse pulmonary vascular remodeling in the Fontan circulation. J Heart Lung Transplant. 2015 Mar; 34(3): 404–13. doi: 10.1016/j.healun.2015.01.005.
- Opotowsky AR. Clinical evaluation and management of pulmonary hypertension in the adult with congenital heart disease. Circulation. 2015 Jan 13; 131(2): 200–10. doi: 10.1161/CIRCULATIONAHA.114.006976.
- Bossone E, D’Andrea A, D’Alto M, et al. Echocardiography in pulmonary arterial hypertension: from diagnosis to prognosis. J Am Soc Echocardiogr. 2013 Jan; 26(1): 1–14. doi: 10.1016/j.echo.2012.10.009.
- Puchalski MD, Williams RV, Askovich B, et al. Assessment of right ventricular size and function: echo versus magnetic resonance imaging. Congenit Heart Dis. 2007; 2(1): 27–31. doi: 10.1111/j.1747-0803.2007.00068.x.
- Hjortshoj CMS, Kempny A, Jensen AS, et al. Past and current cause-specific mortality in Eisenmenger syndrome. Eur Heart J. 2017 Jul 7; 38(26): 2060–67. doi: 10.1093/eurheartj/ehx201.
- Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016 Jan 1; 37(1): 67–119. doi: 10.1093/eurheartj/ehv317.
- Aziz
A,
Gyamfi-Bannerman
C,
Siddiq
Z, et al. Maternal
outcomes by race during postpartum readmissions. Am
J Obstet Gynecol. 2019
May; 220(5): 484
e1–84 e10 . doi: 10.1016/j.ajog.2019.02.016. - Skoro-Sajer N, Gerges C, Balint OH, et al. Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension. Heart. 2018; 104(14): 1195–99. doi: 10.1136/heartjnl-2017-312143.
- Manes A, Palazzini M, Leci E, Bacchi Reggiani ML, Branzi A, Galiè N. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. Eur Heart J. 2014 Mar; 35(11): 716–24. doi: 10.1093/eurheartj/eht072.
- D’Alto M, Diller, GP. Pulmonary hypertension in adults with congenital heart disease and Eisenmenger syndrome: current advanced management strategies. Heart. 2014 Sep; 100(17): 1322–8. doi: 10.1136/heartjnl-2014-305574.
- Giannakoulas G, Boutsikou M. The Gordian knot of thromboembolism in congenital heart disease: Table 1. Heart. 2015 Oct; 101(19): 1523–24. doi: 10.1136/heartjnl-2015-308045.
- Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006 Jul 4; 114(1): 48–54. doi: 10.1161/CIRCULATIONAHA.106.630715.
- Mukhopadhyay S, Nathani S, Yusuf J, Shrimal D, Tyagi S. Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger syndrome-a randomized, placebo-controlled, double-blind crossover study. Congenit Heart Dis. Sep-Oct 2011; 6(5): 424–31. doi: 10.1111/j.1747-0803.2011.00561.x.
- Cha KS, Cho KI, Seo JS, et al. Effects of inhaled iloprost on exercise capacity, quality of life, and cardiac function in patients with pulmonary arterial hypertension secondary to congenital heart disease (the Eisenmenger syndrome) (from the EIGER Study). Am J Cardiol. 2013 Dec 1; 112(11): 1834–9. doi: 10.1016/j.amjcard.2013.08.003.
- Chaix MA, Gatzoulis MA, Diller GP, Khairy P, Oechslin EN. Eisenmenger Syndrome: A Multisystem Disorder-Do Not Destabilize the Balanced but Fragile Physiology. Can J Cardiol. 2019 Dec; 35(12): 1664–74. doi: 10.1016/j.cjca.2019.10.002.
- Dimopoulos K, Inuzuka R, Goletto S, et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation. 2010 Jan 5; 121(1): 20–5. doi: 10.1161/circulationaha.109.883876.
- Dimopoulos K, Wort SJ, Gatzoulis MA. Pulmonary hypertension related to congenital heart disease: a call for action. Eur Heart J. 2014 Mar 14; 35(11): 691–700. doi: 10.1093/eurheartj/eht437.
- Giardini A, Balducci A, Specchia S, Gargiulo G, Bonvicini M, Picchio FM. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J. 2008 Jul; 29(13): 1681–7. doi: 10.1093/eurheartj/ehn215.
- Goldberg DJ, French B, McBride MG, et al. Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: a randomized, double-blind, placebo-controlled, crossover trial. Circulation. 2011 Mar 22; 123(11): 1185–93. doi: 10.1161/CIRCULATIONAHA.110.981746.
- Schuuring MJ, Vis JC, van Dijk AP, et al. Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial. Eur J Heart Fail. 2013 Jun; 15(6): 690–8. doi: 10.1093/eurjhf/hft017.
- Goldberg DJ, Zak V, Goldstein BH, et al.; Pediatric Heart Network Investigators. Results of the FUEL Trial. Circulation. 2020 Feb 25; 141(8): 641–51. doi: 10.1161/circulationaha.119.044352.
- Hebert A, Mikkelsen UR, Thilen U, et al. Bosentan improves exercise capacity in adolescents and adults after Fontan operation: the TEMPO (Treatment With Endothelin Receptor Antagonist in Fontan Patients, a Randomized, Placebo-Controlled, Double-Blind Study Measuring Peak Oxygen Consumption) study. Circulation. 2014 Dec 2; 130(23): 2021–30. doi: 10.1161/CIRCULATIONAHA.113.008441.
DOI: https://doi.org/10.14797/UFEJ2329 | Journal eISSN: 1947-6108
Language: English
Page range: 145 - 151
Accepted on: Apr 28, 2021
Published on: Jul 1, 2021
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
© 2021 Hassaan B Arshad, Valeria E Duarte, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.